The UK’s National Institute for Health and Care Excellence (NICE) has recommended AliveCor’s KardiaMobile as an option to detect atrial fibrillation (AF) for suspected paroxysmal AF people.

KardiaMobile is a smartphone-based personal electrocardiogram (ECG) solution that can be used to monitor AF at home.

It offers a patchless, wireless and compact solution that can be used anywhere and anytime.

The device is claimed to be the first smartphone-based ECG to be recommended by NICE for use within the National Health Service (NHS).

With this latest approval, physicians and patients across England and Wales will be able to get an ECG recording on their smartphone in 30 seconds with the Kardia app.

AliveCor stated that KardiaMobile provides instant analysis of AF, bradycardia and tachycardia, the leading cardiovascular disease indicators.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AliveCor CEO Priya Abani said: “AliveCor is proud to be able to offer the only NICE-recommended personal ECG to support remote cardiac care services for patients not in front of their cardiologist.

“Today’s recommendation not only highlights the clinical superiority of KardiaMobile against the current standard of care but also its position as a more cost-effective solution, therefore warranting its value as a clinical tool to support rapid diagnosis of AF.”

The company noted that the latest recommendation is based on evidence from 27 different studies, including five randomised controlled trials.

Findings from these studies and trials showed that KardiaMobile was five times more efficacious at detecting problems related to heartbeat than standard tests.

Last July, AliveCor’s KardiaMobile 6L received 510(k) clearance from the US Food and Drug Administration (FDA) for healthcare experts measuring QTc interval in patients.